{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-002424","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.648491+00:00","generated_at":"2026-06-07T04:09:54.101606+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Kymera holds immunology R&D day; discloses new targets and clinical timelines","bullets":["Company held virtual immunology R&D day on Jan 4, 2024, highlighting emerging pipeline.","New target disclosures and supporting preclinical data presented.","Clinical study initiation timing provided for immunology programs.","No financial data or earnings guidance included in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-002424","json":"https://secwatch.observer/filing/0001193125-24-002424.json","markdown":"https://secwatch.observer/filing/0001193125-24-002424.md","text":"https://secwatch.observer/filing/0001193125-24-002424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312524002424/0001193125-24-002424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312524002424/d855441d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:09:54.101606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}